Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolbetuximab plus CAPOX versus placebo plus CAPOX in first-line CLDN18.2-positive, HER2-negative advanced gastric/GEJ adenocarcinoma
2018-000519-26Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Zolbetuximab + CAPOX with Placebo + CAPOX (2 arms). Primary endpoint: Progression-free survival. Started Sep 2018; status: completed.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2018-000519-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000519-26.